HBM Partners related stories
All articles and analysis
Gynesonics Closes $21 Mln Financing RoundHBM Partners led a $21 million Series D financing round for Gynesonics. Correlation Ventures, a new investor, took part in the financing as well as existing investors Abingworth, Advanced Technology Ventures (ATV) and InterWest Partners. Redwood City, Calif.-based Gynesonics is a women’s healthcare company that develops minimally invasive solutions for symptomatic uterine fibroids.
- Gynesonics Raises $21M
Gynesonics Inc., a women’s healthcare company, has raised a $21 million Series D round led by HBM Partners. New investor Correlation Ventures and existing investors Abingworth, Advanced Technology Ventures and InterWest Partners also participated. The money will be used for clinical and commercial development of the company’s treatment for uterine fibroids.
- Delenex Therapeutics Closes $14M Series A Funding Round
Delenex Therapeutics AG completed its Series A funding round at CHF 13.5 million ($14 million). SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners led the financing. Delenex is a Zurich-Schlieren, Switzerland-based biotechnology company that develops therapeutic antibody fragments.
- Gemin X Adds $16 Million
Gemin X Pharmaceuticals Inc., an oncology drug developer with offices in both Malvern, Pa. and Montreal, has raised $16 million in Series D funding. The deal also includes an investor option to invest an additional $4 million. Return backers Caxton Advantage Life Sciences Fund and Sanderling Venture Partners co-led the round. The company has now raised over $100 million, from Caxton, Sanderling, H.I.G. Ventures, CDP/Vantage Point, ProQuest, Merlin BioMed Group, HBM Partners, Canadian Medical Discoveries Fund, Ontario Teachers' Pension Plan Board, SoftBank Life Science, Business Development Bank of Canada, Solidarity Fund QFL and Pinnacle Bioventures.
- Nabriva Therapeutics Raises €15 Million
Nabriva Therapeutics, a Vienna, Austra-based developer of antibiotics for treating resistant pathogens, has raised €15 million in new VC funding. Return backers include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund. The company has now raised a total of €57.4 million since 2006.
- peHUB Wire: Thursday, October 29, 2009
Random Ramblings
- peHUB Wire: Thursday, October 29, 2009
Random Ramblings
Mittelstand sparks private equityAccording to a recent study, Germany’s private equity industry may be surviving the credit crunch better than some other countries. But the country still faces major challenges, both in terms of private equity activity and the wider economy, as exports continue to be hit hard by the global downturn.
- HBM seeks buyer for Brahms
Diagnostics company on the block
- Merck Backs Odyssey Thera
Odyssey Thera Inc., a San Ramon, Calif.-based provider of drug development technology, has raised an undisclosed amount of new VC funding. Merck & Co. was joined by return backers Burrill & Company, HBM Partners and Healthcap. The company had previously raised around $18 million.